Xencor reported $-51.05M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Arrowhead Research USD 57.17M 7.03M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Cytokinetics USD -169.32M 19.48M Mar/2026
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -30.2M 52.15M Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Xencor USD -51.05M 55.28M Dec/2025